Owkin announced on Thursday the launch of ATLANTIS, an AI-powered multimodal patient data discovery programme that analyses and extracts knowledge from complex medical data, including imaging, genomics, clinical records and more. The information gleaned from ATLANTIS will be leveraged by Owkin's "AI co-pilot," Owkin K, to accelerate drug discovery and diagnostics.According to the company, ATLANTIS was designed to overcome the challenge of data being siloed across different institutions and departments. It noted that while AI can drive innovation by utilising rich, unified datasets, this becomes a challenge when data is fragmented and inaccessible.ATLANTIS will map data in 11 therapeutic areas, including seven in oncology: non–small-cell lung cancer, head and neck squamous cell carcinoma, breast cancer, prostate cancer, ovarian cancer, pancreatic cancer and multiple myeloma; three in immunology: ulcerative colitis, Crohn's disease and systemic lupus erythematosus; and one in neurology: Alzheimer's disease.A consortium of 20 international healthcare institutions has come together with ATLANTIS to bolster their AI research efforts and derive deeper insights from their multimodal data, fueling advancements in medical discovery. In a post on LinkedIn, Owkin CEO Thomas Clozel named a number of these institutions, including Cooper University Health Care, the Balearic Islands Health Research Institute Foundation, the Vall d'Hebron Research Institute, CuriMeta Inc., Washington University in St. Louis, The Girona Biomedical Research Institute, The Royal Marsden NHS Foundation Trust, The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Leipzig University, Sheba Medical Center, Aster Insights and Navarrabiomed."Owkin is committed to fostering collaboration between data scientists and patient data to achieve unparalleled insights and innovation," said Agathe Arlotti, SVP of Partnerships at Owkin. "By combining our AI expertise with leading healthcare partners, we are creating a patient data network that pushes the boundaries of biomedical research. Together, we are fueling breakthroughs for patients."Initiated in September 2024, ATLANTIS is expected to be complete by May 2025. Last month, Owkin dosed the first cancer patient in a Phase I trial with OKN4395, an AI-developed triple inhibitor of EP2/EP4 and DP1. Once complete, ATLANTIS could power similar discoveries with novel data supplied to Owkin K. The tech bio also announced a partnership with fellow generative AI drug discovery firm Absci last month, combining platforms to accelerate the discovery and design of novel therapeutics.
